- Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP
-
Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH, Jin UR, Park JS
- KMID: 2069930
- J Korean Med Sci.
- 2014 Nov;29(11):1493-1500.
- doi: 10.3346/jkms.2014.29.11.1493
Febrile neutropenia (FN) is the major toxicity of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen in the treatment of diffuse large B-cell lymphoma (DLBCL). The prediction of neutropenia... -
- CITED
-
- Close
- SHARE
-
- Close
